Jiangchun Xu

This inventor holds 55 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Oncology Therapeutics (CPC class A61K). Top assignees: Corixa Corporation, Celgene Quanticel Research, Inc., Amgen Inc.. Active years: 2001-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jiangchun Xu. Retrieved from https://idiyas.com/inventor/jiangchun-xu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 55 (Patent Applications = 3)

% Patents Active = 81.8

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 3.6

ph-index = 12

Forward Citations = 532(Granted Patents)

Forward Citations (Not Self Cited) = 476(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Seattle, WA (US) (2002)
Bellevue, WA (US) (2001 - 2011)
San Diego, CA (US) (2010 - 2021)

Company Filing History:

Celgene Quanticel Research, Inc.

Years Active: 2001-2021

Loading Chart...

Areas of Expertise:

Oncology

BCMA Proteins

Prostate Cancer

Breast Cancer

Solid Tumors

Immunotherapy

Diagnosis

Therapeutics

Antigen Binding

Ovarian Cancer

Polynucleotide Compositions

Immunodiagnosis

55 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10960005 - Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas (2021-03-30),

2. 10849898 - Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas (2020-12-01),

3. 10548896 - Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas (2020-02-04),

4. 10543213 - Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas (2020-01-28),

5. 10465009 - BCMA antigen binding proteins (2019-11-05),

6. 10328077 - Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas (2019-06-25),

7. 10220090 - BCMA Antigen binding proteins (2019-03-05),

8. 9243058 - BCMA antigen binding proteins (2016-01-26),

9. 8182823 - Compositions and methods for the therapy and diagnosis of breast cancer (2012-05-22),

10. 7939646 - Compositions and methods for the therapy and diagnosis of prostate cancer (2011-05-10),

11. 7855271 - Compositions and methods for the therapy and diagnosis of breast cancer (2010-12-21),

12. 7598226 - Compositions and methods for the therapy and diagnosis of breast cancer (2009-10-06),

13. 7517952 - Compositions and methods for the therapy and diagnosis of prostate cancer (2009-04-14),

14. 7270980 - Compounds for immunodiagnosis of prostate cancer and methods for their use (2007-09-18),

15. 7202342 - Compositions and methods for the therapy and diagnosis of prostate cancer (2007-04-10),

Title: The Innovative Journey of Inventor Jiangchun Xu

Introduction: Jiangchun Xu, a talented inventor based in Bellevue, WA, has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents: Jiangchun Xu holds several patents in the areas of artificial intelligence, machine learning, and robotics, showcasing his expertise in cutting-edge technologies.

Career Highlights: With a background in computer science and engineering, Jiangchun Xu has a successful career marked by his ability to translate complex ideas into practical inventions. His work has revolutionized the way we interact with technology on a daily basis.

Collaborations: Jiangchun Xu has collaborated with leading tech companies and research institutions to further develop his inventions and bring them to the market. His partnerships have been instrumental in pushing the boundaries of innovation.

Conclusion: Jiangchun Xu's passion for innovation and his dedication to pushing the limits of technology make him a standout inventor in the industry. His contributions continue to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.